Navigation Links
NTI in Medical News

National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio, August 31-September 1

...n, MD, University of Pittsburgh Medical Center; Dr. Ronald Stewart, MD, FACS, University of Texas Health Science Center at San Antonio and nti Board Chairman COL Lorne Blackbourne, Commander U.S. Army Institute of Surgical Research Registration information and confer...

ARTHUR(R) and CVS Caremark Debut the Winner of the 'ARTHUR/All Kids Can Character Search' June 30 on PBS KIDS GO!(SM)

...RTHUR ARTHUR, based on Marc Brown's best-selling books, is the highest rated weekday children's series on PBS among children 6-11 (Source: For PBS, nti Pocketpiece, October 2007-June 2008). ARTHUR has won numerous awards, including the George Foster Peabody Award, a BAFTA and six Daytime Emmys--four f...

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

...e 3 clinical trials as a potential new drug to treat acute ischemic stroke. nti has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. nti has rights to receive payments from an approved drug for Alzheimer's diseas...

Cherrybrook Kitchen Announces New Partnership With Arthur

...HUR ARTHUR, based on Marc Brown's best-selling books, is the highest rated weekday children's series on PBS among children 6-11 (Source: For PBS, nti Pocketpiece, October 2007-June 2008). ARTHUR has won numerous awards, including the George Foster Peabody Award, a BAFTA and six Daytime Emmys -- four...

Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO

...mpany's Acting Chief Executive Officer. Mr. Fletcher has been a director of nti since February 2007. With the Acting CEO appointment, the board of director...linical trials for evaluation as a new drug to treat acute ischemic stroke. nti has an early-stage development program for Alzheimer's disease and rights t...

Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy

...s Michael J. Kosnett , University of Colorado, Denver and Colorado School of Public Health Erli Chen , Nanotechnology Commercialization Group, nti Gary Marchant , Arizona State University Diana Bowman , Monash University Steffi Friedrichs , Nanotechnology Industries Association John...

Neurobiological Technologies Reports Second Quarter Financial Results

...e well tolerated for acute ischemic stroke. Conference Call Information nti will webcast its quarterly financial results and host a conference call on .... Replay access code: 3898964. About Neurobiological Technologies, Inc. nti is a biopharmaceutical company focused on developing novel agents for centr...

Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.

... Medical Officer, effective as of November 26, 2007. Dr. Wasiewski joined nti in February 2007 as Vice President, Clinical Programs with primary responsi...rsity of New York, at Buffalo. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and ...

Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards

...DAQ Listing Qualifications Department had notified nti that it was not in compliance with the $35 million...f listed securities continued listing requirement. nti regained compliance following the closing on Novem... stock. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expe...

Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine

...nd a 6% increase over last quarter. Under an exclusive marketing agreement, nti receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and ...

More>>

NTI in Medical Technology

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

...l studies of XERECEPT in brain tumor models. nti sold the worldwide rights and assets related to XE...er 2005. If Celtic Pharma commercializes XERECEPT, nti is entitled to receive milestone payments upon the achievement of certain regulatory approvals and nti is also entitled to receive profit-sharing payment...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

...s disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on c...potential new drug to treat acute ischemic stroke. nti has more recently chosen not to extend its early-s...rograms for Huntington's and Alzheimer's diseases. nti has rights to receive payments from an approved dr...

Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis

.... As a result, the company has terminated further enrollment in the trials. nti will obtain and analyze the data before evaluating the potential for any fu...ischemic stroke; the future development of Viprinex is under consideration. nti also has early- stage development programs for Alzheimer's and Huntington's...

Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009

...), as well as other risks detailed from time to time in NTI's Securities and Exchange Commission filings. Copies of these filings are available from nti upon request. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of r...

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

...cted to be completed in the first quarter of 2009, nti will not perform a superiority analysis during the...ial's final analysis." Conference Call Details nti will hold a conference call to discuss this develo...tients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzh...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

... Austria, are from a retrospective analysis led by nti scientists of two previous Phase 3 clinical trials... more than 1700 patients and were conducted before nti acquired the rights to ancrod. The STAT trial in t...ntry. "The conclusions of this analysis provided nti with the information needed to revise the dosing r...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

...e the benefit required for approval. If the trials are allowed to continue, nti will not have access to any unblinded patient data until the trials are com...diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's ...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

...e the time period that patients can be treated after the onset of a stroke. nti also has the right to receive royalty payments from sales of Namenda(R) (me...inical development for swelling associated with brain tumors. Additionally, nti has rights to two compounds in early-stage development for Alzheimer's and ...

Celtic Pharma Provides Update on XERECEPT(R) Clinical Program

...red the rights and assets related to XERECEPT from nti in November 2005, issued the following press relea...nounced the discontinuation of enrollment in study nti 0302, a Phase III randomized, double-blind study c...ecision. The decision is unrelated to the on-going nti 0303 Phase III study, which is now close to comple...

Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

...c Stroke by David E. Levy, MD (Neurobiological Technologies) nti is moving forward with two international, randomized, double-blind, placebo...www.ntii.com/">http://www.ntii.com . A full press kit is available at the nti booth (#171) or by emailing: nti also announced that it has amended its stockholder...ed under the plan. Conference Call Information nti will webcast its quarterly financial results and h... which there are few acceptable treatment options. nti also has early-stage development programs for Alzh...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...nex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's di...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...rate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine...diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's ...

More>>

Other Tags
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... Baty, “The Safety Chick” who profiled a handful ... Safe-Listening Earphones from Etymotic Research. This year, many ... list, and Etymotic, an innovator of hearing wellness ... ears. Their ETY•Kids Safe-Listening Earphones, offered in yellow, ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... 2014 The microbiology testing sector is ... diagnostics industry; it is also the hugest challenge facing ... the ongoing spread of AIDS – still the world’s ... the upsurge of opportunistic infections (OIs); bioterrorism threat; advancements ... of immunosuppressive medicines. Although for certain infections the etiology ...
(Date:8/29/2014)... News) -- Prostate cancer patients lacking knowledge about the ... lead to worse quality of care and long-term results, ... with a median age of 63. All were newly ... the disease was associated with greater difficulty deciding which ... would be effective, the study found. "For prostate ...
(Date:8/29/2014)... 2014 Edvance360, a leading provider of ... online teaching, as well as 2011 winner and six-time-finalist ... Management System, announced that Brooke Education Services, Northwest Academy, ... Interactive Advertising Bureau of Canada (IAB Canada), StarSVCS, and ... are delighted to welcome each new client to the ...
Breaking Medicine News(10 mins):Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
(Date:8/29/2014)... nucleus, chromosomal DNA is tightly bound to structural ... chromatin. Until about two decades ago, histones were ... material around which the glamorous DNA strands were ... appreciation for how DNA/histone interactions govern gene expression. ... studying the sequence of the genome from cancer ...
(Date:8/29/2014)... the Tibetan plateau -- the largest topographic anomaly above ... its profound effect on climate and its reflection of ... Bulletin , Katharine Huntington and colleagues employ a cutting-edge ... and fossil snail shells to investigate the uplift history ... Views range widely on the timing of surface uplift ...
(Date:8/28/2014)... of America (ESA) is pleased to announce the selection ... the Society. Honorary Membership acknowledges those who have served ... in the affairs of the Society that has reached ... by the ESA Governing Board and then voted on ... at the Awards Ceremony at Entomology 2014, ESA,s Annual ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
Other Contents